上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
ZX-29 纯度: 99.52%
ZX-29 是一种有效的选择性的 ALK 抑制剂,对 ALK,ALK L1196M 和 ALK G1202R 的 IC50 分别为 2.1 nM,1.3 nM 和 3.9 nM,但对 EGFR 无活性。ZX-29 通过诱导内质网应激来诱导细胞凋亡 (apoptosis),并克服了由 ALK 突变引起的细胞抗性。ZX-29 还可诱导保护性自噬 (autophagy) 并具有抗肿瘤作用。
ZX-29 Chemical Structure
CAS No. : 2254805-62-2
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
5 mg | ¥3000 | In-stock | |
10 mg | ¥4800 | In-stock | |
25 mg | ¥9500 | In-stock | |
50 mg | ¥14500 | In-stock | |
100 mg | 询价 | ||
200 mg | 询价 |
* Please select Quantity before adding items.
ZX-29 相关产品
•相关化合物库:
- Bioactive Compound Library Plus
- Apoptosis Compound Library
- Kinase Inhibitor Library
- Protein Tyrosine Kinase Compound Library
- Anti-Cancer Compound Library
- Autophagy Compound Library
- Endoplasmic Reticulum Stress Compound Library
- Anti-Lung Cancer Compound Library
生物活性 |
ZX-29 is a potent and selective ALK inhibitor with an IC50 of 2.1 nM, 1.3 nM and 3.9 nM for ALK, ALK L1196M and ALK G1202R mutations, respectively. ZX-29 is inactive against EGFR. ZX-29 induces apoptosis by inducing endoplasmic reticulum (ER) stress and overcomes cell resistance caused by an ALK mutation. ZX-29 also induces protective autophagy and has antitumor effect[1]. |
IC50 & Target |
IC50: 2.1 nM (ALK), 1.3 nM (ALK L1196M) and 3.9 nM (ALK G1202R)[1] |
||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
ZX-29 (0-81 nM; 24-72 hours; NCI-H2228 cells) treatment leads to a time- and dose-dependent decrease in NCI-H2228 cell viability[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay[1]
Cell Autophagy Assay[1]
Cell Cycle Analysis[1]
Apoptosis Analysis[1]
Western Blot Analysis[1]
RT-PCR[1]
|
||||||||||||||||||||||||||||||||||||||||||||||||
体内研究 (In Vivo) |
ZX-29 (50 mg/kg; intragastric administration; every 2 days; for a total of 7 times; female BALB/c nude mice) treatment suppresses tumor growth in a mouse xenograft model[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||||||||||||||||||||||||||||||||||
分子量 |
518.03 |
||||||||||||||||||||||||||||||||||||||||||||||||
Formula |
C23H28ClN7O3S |
||||||||||||||||||||||||||||||||||||||||||||||||
CAS 号 |
2254805-62-2 |
||||||||||||||||||||||||||||||||||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||||||||||||||||||||||||||||||||||
储存方式 |
4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
||||||||||||||||||||||||||||||||||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 50 mg/mL (96.52 mM; ultrasonic and warming and heat to 60°C) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||||||||||||||||||||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务